General
Preferred name
bucladesine
Synonyms
Dibutyryl-cAMP, sodium salt ()
Bucladesine (calcium salt) ()
Dibutyryl-cAMP calcium salt ()
DC2797 calcium salt ()
dbcAMP ()
Dibutyryl-cAMP sodium salt ()
Dibutyryl-cAMP ()
DC2797 ()
Sodium dibutyryl cAMP ()
Bucladesine sodium salt ()
Bucladesine (sodium) ()
Bucladesine (calcium) ()
Dibutyryl cAMP (sodium salt) ()
DBcAMP (sodium salt) ()
Dibutyryl cAMP (calcium salt) ()
DBcAMP (calcium salt) ()
Bucladesine calcium salt ()
BUCLADESINE SODIUM ()
Bucladesine (sodium salt) ()
Dibutyryl camp ()
Bucladesina ()
DT-5621 ()
NSC-143108 ()
P&D ID
PD014073
CAS
16980-89-5
19436-29-4
362-74-3
938448-87-4
Tags
available
drug
Drug Status
approved
experimental
investigational
Max Phase
2.0
Drug indication
Cardiovascular disease
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing[1][2][3][4].
DESCRIPTION
Bucladesine calcium salt (Dibutyryl-cAMP calcium salt;DC2797 calcium salt) is a cell-permeable cyclic AMP (cAMP) analog and selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine calcium salt acts as a phosphodiesterase (PDE) inhibitor.
PRICE
29
DESCRIPTION
Microtubule inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Cell-permeable cAMP analog
(Tocriscreen Plus)
DESCRIPTION
Cell-permeable cAMP analog
(Tocriscreen Total)
DESCRIPTION
Bucladesine calcium salt is a membrane permeable selective activator of PKA. It is absorbed very rapidly and almost completely when the aqueous solution is applied to the site where the skin has been excised. Besides, it is capable of significantly reducing the inflammatory oedema in the arachidonic acid induced ear oedema model in mice.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Bucladesine sodium (DC2797) is a cAMP analog with cell-permeable properties. Bucladesine sodium is also a cAMP-dependent protein kinase (PKA) activator and a phosphodiester (PDE) inhibitor. Bucladesine sodium has anti-inflammatory activity.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
17
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
NPC Screening Collection
Other bioactive compounds
ReFrame library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
69
Molecular Weight
469.14
Hydrogen Bond Acceptors
11
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
2
cLogP
1.69
TPSA
163.99
Fraction CSP3
0.61
Chiral centers
5.0
Largest ring
6.0
QED
0.45
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Cell Biology
Pathway
Metabolism
Tyrosine Kinase/Adaptors
Metabolic Enzyme/Protease
Stem Cell/Wnt
TGF-beta/Smad
Primary Target
cAMP
MOA
PKA activator
adenosine receptor agonist, cAMP stimulant
Indication
skin ulcer
Target
PRKACA
Phosphodiesterase (PDE)
PKA
Apoptosis
phosphodiesterase
Source data
